Livzon Group

Livzon Pharmaceutical (A-share code: 000513.SZ; H-share code: 01513.HK) is a large comprehensive pharmaceutical group covering pharmaceutical R&D, production, and commercialization. It is also a pharmaceutical listed company dual-listed on the Shenzhen Stock Exchange and the Hong Kong Stock Exchange. Its products broadly cover chemical drugs, biological drugs, and traditional Chinese medicine. In the fiscal year 2025, the company achieved an operating revenue of RMB 12.020 billion and a net profit of RMB 2.009 billion.


To continuously enhance innovation capabilities and accelerate transformation and upgrading, Livzon Pharmaceutical has been increasing R&D investment. It has successively established the "National Recognized Enterprise Technology Center," "National and Local Joint Engineering Center for Long-acting Microspheres," "National Engineering Technology Research Center for Modernization of Traditional Chinese Medicine," and "Livzon Group Postdoctoral Research Workstation," building a competitive R&D innovation system.


In the field of chemical drugs, Livzon Pharmaceutical pioneered the development of Yilian® (Ilaprazole), China's first 1.1-class innovative drug in the digestive field, ushering in the era of innovative PPI acid-suppression therapy in China. The company focuses on the development of innovative drugs, high-barrier complex formulations, and products with high clinical value, laying out its portfolio around digestive, mental/neurological, assisted reproduction, anti-infection, and chronic diseases such as autoimmune, metabolic, and cardiovascular/cerebrovascular fields, thereby building a product matrix with international competitiveness. In recent years, the company has established a pipeline covering multiple Class 1 innovative drugs through self-research and BD, and has positioned products with "first-in-class" or "best-in-class" potential. Meanwhile, as a leading microsphere formulation enterprise in China, Livzon has built the National and Local Joint Engineering Center for Long-acting Microsphere Technology. After ten years of arduous R&D, it has successively launched improved new drugs Weibaoning® and Aliwei®.


In the field of biological drugs, the company focuses on autoimmune diseases, infectious disease prevention, and assisted reproduction, concentrating on novel molecules, novel targets, and differentiated molecular design. It has multiple biological new drug projects under development and has established four platforms: "early drug discovery, druggability assessment, integrated upstream and downstream R&D and quality evaluation of macromolecular protein drugs, and innovative vaccine technology." It has also built commercial production bases for recombinant protein drugs and vaccines, covering the entire biological drug R&D process.


In the field of traditional Chinese medicine (TCM), as a pioneer in the modernization transformation of Chinese medicine, Livzon continuously deepens its practices in TCM innovation and industrialization. It has formed a three-dimensional product matrix covering innovative TCM, classic famous formulas, and health products. It has launched over twenty exclusive TCM products, including Shenqi Fuzheng Injection, China's first pure TCM clear large-volume infusion preparation, and Livzon antiviral granules. The company is currently accelerating the development of over ten new TCM drugs in Categories 1.1 and 3.1.


Through continuous innovation, Livzon has achieved fruitful R&D outcomes, receiving 2 national science and technology awards and 5 provincial/ministerial-level awards. Among them, the projects "R&D and Industrialization of Original Innovative Drug Ilaprazole" and "Research and Application of Triterpenes and Saponins from Chinese Medicine and Natural Products" won the second prize of the National Science and Technology Progress Award. Honors such as "Top 10 in China's Biological Drug R&D Strength, Top 100 in China's Chemical Drug R&D Strength, Landmark Achievement Award of China's Pharmaceutical Science and Technology in the 13th Five-Year Plan, and Top 100 Enterprise in China's Pharmaceutical Industry" are high recognition from various sectors of society for Livzon's pharmaceutical R&D innovation.


Livzon Pharmaceutical will take "patient life quality first" as its mission and "be a leader in pharmaceuticals" as its vision, developing more innovative products to benefit more patients, and contributing to the development of China's national pharmaceutical industry and the cause of human life and health!